The Joint Corp. Reports Second Quarter 2026 Financial Results
Rhea-AI Summary
The Joint Corp. (NASDAQ: JYNT) reported second quarter 2026 revenue of $15.2 million, up 14% year over year, while system-wide sales declined 3.7% to $128.0 million. Reported comp sales were (2.8)%, a 140-basis-point improvement versus first quarter 2026.
Consolidated net income rose to $653,000 (EPS $0.05) versus $93,000, while net loss from continuing operations narrowed to $251,000 from $1.0 million. Adjusted EBITDA from continuing operations increased to $1.5 million from $88,000. Operating cash flow grew to $2.2 million, driving free cash flow of $1.9 million. The company repurchased about 82,000 shares for $677,000 and completed three regional developer territory buybacks, advancing its transition to a capital-light, pure-play franchisor model.
Positive
- Revenue +14% YoY to $15.2 million in Q2 2026
- Consolidated net income up to $653,000 from $93,000 YoY
- Net loss from continuing ops improved to $251,000 from $1.0 million
- Adjusted EBITDA continuing ops rose to $1.5 million from $88,000
- Operating cash flow increased to $2.2 million; free cash flow $1.9 million
- Unrestricted cash of $22.2 million plus $20 million undrawn credit line
Negative
- System-wide sales declined 3.7% YoY to $128.0 million in Q2
- Comp sales negative at (2.8)% despite sequential improvement
- Selling and marketing expense up 40% YoY to $4.9 million
- More clinic closures than openings: 5 opened, 7 closed in Q2
- Guided clinic count expected lower at 2026 year end versus 2025
- Net loss from continuing operations persists at $251,000 in Q2
News Explained
As of August 5, 2026, refranchising was substantially complete, with 13 Southern California and 15 Southeast clinics still pending lease assignments.
The Joint Corp. said its refranchising initiative was substantially complete as of
That characterization does not mean every clinic transfer had closed: the remaining clinics were still under management service agreements, and the Northern California bundle had only a signed asset purchase agreement.
At
The specific completion items are final lease assignments or reassignments for the Southern California and Southeast clinics and closing of the Northern California bundle.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 earnings | Positive | +0.2% | Revenue and net income increased while comp sales remained negative. |
| Mar 12 | Q4 earnings | Positive | +2.3% | Quarterly and full-year results showed higher income and adjusted EBITDA. |
| Nov 06 | Q3 earnings | Positive | -3.9% | Adjusted EBITDA rose despite softer comp sales and revised 2025 guidance. |
| Aug 07 | Q2 earnings | Positive | +0.4% | Revenue and adjusted EBITDA improved alongside the pure-play franchisor transition. |
| Jul 30 | Restatement announcement | Negative | -4.0% | Planned restatement identified material weaknesses in internal control and disclosure controls. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings reactions were mixed, with four aligned events and one divergence; the average move was -0.99%.
Key Terms
adjusted ebitda financial
free cash flow financial
comp sales financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Consolidated Net Income Increases
Adjusted EBITDA From Continuing Operations Increases by
- Cash Flow from Operating Activities Rises
- Delivered on Capital Allocation Priorities with Regional Developer Territory Buybacks and
SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of chiropractic care through The Joint Chiropractic® network, today reported financial results for the second quarter ended June 30, 2026. The following figures represent continuing operations unless otherwise stated.
Second Quarter 2026 Financial Highlights
- Revenues grew to
$15.2 million , a14% increase compared to the second quarter of 2025. - System-wide sales1 were
$128.0 million , a3.7% decrease compared to the second quarter of 2025. - Reported comp sales2 of (2.8)%, a 140-basis point improvement compared to the first quarter of 2026.
- Net income from consolidated operations was
$653,000 , compared to$93,000 in the second quarter of 2025. Net loss from continuing operations was$251,000 , compared to a net loss of$1.0 million in the second quarter of 2025. - Adjusted EBITDA (a non-GAAP metric) from consolidated operations was
$3.2 million , in line with$3.2 million in the second quarter of 2025. Adjusted EBITDA from continuing operations was$1.5 million , compared to$88,000 in the second quarter of 2025. - Cash flow from operating activities improved to
$2.2 million compared to$869,000 in the second quarter of 2025, and free cash flow (a non-GAAP metric) was$1.9 million compared to$364,000 in the second quarter of 2025. - Repurchased 82,000 shares for total consideration of approximately
$677,000 , at an average of$8.23 per share during the second quarter. - Completed three regional developer (“RD”) territory buybacks in the second quarter.
Second Quarter 2026 Operating Highlights
- Total clinic count was 941 at June 30, 2026.
- Opened five clinics, closed seven clinics, and refranchised 29 clinics during the quarter, for a total of 896 franchised clinics and 45 company-owned or managed clinics at June 30, 2026.
- Increased adoption of the Company’s more flexible plan options continues to drive significantly stronger patient retention rate.
“In the second quarter, we continued to see the benefits of our Joint 2.0 strategy take hold, with our actions to optimize the clinic portfolio, streamline our operating structure, and elevate the patient experience driving improved operating efficiency and strong free cash flow,” said President and Chief Executive Officer of The Joint Corp., Sanjiv Razdan. “We are encouraged with another quarter of revenue growth, as well as the improvement in comp trends compared to the first quarter. We are also seeing the early benefits of our flexible membership options, which contributed to strengthening patient retention. In addition, our national marketing initiative is leveraging consumer research to uncover emerging patient trends, ensuring our offerings align with what patients are seeking from chiropractic care.
“As we enter the second half of 2026, we expect our pure-play franchisor model to drive margin improvement, profitability and continued free cash flow. Our balance sheet remains strong, with
Update on Refranchising Efforts
The Company has substantially completed the refranchising initiative under its Joint 2.0 strategy through three previously announced clinic sale bundles:
- Southern California Bundle: As of August 5, 2026, the buyer has assumed ownership of 32 clinics, with the remaining 13 clinics currently operated by the buyer under Management Service Agreements pending finalization of lease assignments.
- Northern California Bundle: A signed Asset Purchase Agreement is in place for these four clinics.
- Southeast Bundle: As of August 5, 2026, the buyers have assumed ownership of six clinics, with the remaining 15 clinics currently operated by the buyers under Management Service Agreements pending finalization of lease reassignments.
As a result of these refranchising efforts, The Joint Corp. now effectively operates as a capital-light, pure-play franchisor, allowing management to concentrate fully on driving growth through franchise system support, new patient acquisition, and long-term network development.
Financial Results for Second Quarter Ended June 30, 2026 Compared to June 30, 2025
Revenue totaled
Selling and marketing expenses were
Consolidated net income was
Adjusted EBITDA from consolidated operations was
Balance Sheet and Stock Repurchase Program
Unrestricted cash was
During the second quarter of 2026, the Company repurchased approximately 82,000 shares for total consideration of approximately
Financial Results for Six Months Ended June 30, 2026 Compared to June 30, 2025
Revenue was
Adjusted EBITDA from consolidated operations increased to
2026 Guidance
The Company reiterated its 2026 financial guidance as originally provided on March 12, 2026, as follows:
- System-wide sales are expected to be between
$519 million and$552 million . - System-wide comp sales for clinics open 13 months or more are expected to be in the range of (3)% to
3% . - Consolidated Adjusted EBITDA is expected to be in the range of
$12.5 million to$13.5 million .
New franchised clinic openings, excluding the impact of refranchised clinics, are now expected to be in the range of 22 to 26. The Company is working with franchise owners to optimize the performance of the existing franchised clinic base. This will include closing underperforming clinics this year, which will result in the overall clinic count at 2026 year end being lower than 2025 year end.
Conference Call
The Joint Corp. management will host a conference call at 5:00 p.m. ET on Thursday, August 6, 2026, after the market close. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing (800) 715-9871 or (646) 307-1963 and using conference ID: 5033381 approximately 15 minutes prior to the start time. The live webcast of the call, including the accompanying slide presentation, can be accessed directly here.
A replay of the webcast will be archived on the Company’s investor relations website for approximately one year. An audio replay of the conference call will be available through Thursday, August 13, 2026, and can be accessed by dialing (855) 669-9658 or (412) 317-0088 and entering conference ID 4782858.
About The Joint Corp. (NASDAQ: JYNT)
The Joint Corp. (NASDAQ: JYNT) revolutionized access to chiropractic care when it introduced its retail healthcare business model in 2010. Today, it is the nation’s largest operator, manager and franchisor of chiropractic clinics through The Joint Chiropractic network. The Company is making quality care convenient and affordable, while eliminating the need for insurance, for millions of patients seeking pain relief and ongoing wellness. Headquartered in Scottsdale and with over 940 locations nationwide and more than 14 million patient visits annually, The Joint Chiropractic is a key leader in the chiropractic industry. The brand is consistently named to Franchise Times’ annual “Top 400” and “Fast & Serious” list of smartest growing brands. Entrepreneur named The Joint “No. 1 in Chiropractic Services,” and it is regularly ranked on the publication’s “Franchise 500®,” “Fastest-Growing Franchises,” and “Best of the Best” lists, as well as its “Top Franchise for Veterans” and “Top Brands for Multi-Unit Owners” rankings. SUCCESS® named the Company one of the “Top 50 Franchises”. The Joint Chiropractic is an innovative force where healthcare meets retail. For more information, visit www.thejoint.com. To learn about franchise opportunities, visit www.thejointfranchise.com.
Business Structure
The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Tennessee, Washington, and West Virginia, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.
Commonly Discussed Performance Metrics
This release includes a presentation of commonly discussed performance metrics. System-wide sales include revenues at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company’s financial performance because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the revenues from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.
Non-GAAP Financial Information
This release also includes a presentation of non-GAAP financial measures. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the company’s underlying operating performance and operating trends. Free cash flow is presented as a supplemental measure of liquidity. Reconciliation of historical net income/(loss) to EBITDA, Adjusted EBITDA and free cash flow is presented in the tables below. The company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses. The company defines Adjusted EBITDA as EBITDA before acquisition-related expenses (which includes contract termination costs associated with reacquired RD rights), net (gain)/loss on disposition or impairment, stock-based compensation expenses, costs related to restatement filings, restructuring costs, and litigation expenses (consisting of legal and related fees for specific proceedings that arise outside of the ordinary course of our business). The company defines free cash flow as net cash provided by (used in) operating activities less capital expenditures. EBITDA, Adjusted EBITDA and free cash flow do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States (“GAAP”). While EBITDA and Adjusted EBITDA are used as measures of financial performance and free cash flow is used as a measure of liquidity, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA, Adjusted EBITDA and free cash flow should be reviewed in conjunction with the company’s financial statements filed with the Securities and Exchange Commission (the “SEC”). Please refer to the reconciliations of non-GAAP financial measures to their GAAP equivalents located at the end of this release. This release includes forward-looking guidance for certain non-GAAP financial measures, including Adjusted EBITDA. These measures will differ from net income (loss), determined in accordance with GAAP, in ways similar to those described in the reconciliations at the end of this release. We are not able to provide, without unreasonable effort, guidance for net income (loss), determined in accordance with GAAP, or a reconciliation of guidance for Adjusted EBITDA to the most directly comparable GAAP measure because the company is not able to predict with reasonable certainty the amount or nature of all items that will be included in net income (loss).
Forward-Looking Statements
This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Words such as "anticipates," "believes," "continues," "estimates," "expects," "goal," "objective," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. Specific forward-looking statements made in this press release include, among others, our belief that in the second quarter, we continued to see the benefits of our Joint 2.0 strategy take hold, with our actions to optimize the clinic portfolio, streamline our operating structure, and elevate the patient experience driving improved operating efficiency and strong free cash flow; our belief that we are encouraged with another quarter of revenue growth, as well as the strengthening of comp trends as we exited the second quarter; our belief that we are seeing the early benefits of our flexible membership options, which contributed to strengthening patient retention; our belief that our national marketing initiative is leveraging consumer research to uncover emerging patient trends, ensuring our offerings align with what patients are seeking from chiropractic care; our expectation that as we enter the second half of 2026, our pure-play franchisor model will drive margin improvement, profitability and continued free cash flow; our belief that our balance sheet remains strong, with
Investor Contact:
Richard Land, Alliance Advisors IR, thejointinvestor@allianceadvisors.com (212)-838-3777
– Financial Tables Follow –
| THE JOINT CORP. CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| June 30, 2026 | December 31, 2025 | ||||||
| ASSETS | (unaudited) | ||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 22,157,203 | $ | 23,601,810 | |||
| Restricted cash | 846,359 | 700,058 | |||||
| Accounts receivable, net | 2,407,080 | 2,849,864 | |||||
| Deferred franchise and regional development costs, current portion | 895,572 | 945,933 | |||||
| Prepaid expenses and other current assets | 2,735,610 | 1,744,556 | |||||
| Discontinued operations current assets ( | 14,760,981 | 22,246,318 | |||||
| Total current assets | 43,802,805 | 52,088,539 | |||||
| Property and equipment, net | 2,823,232 | 3,159,226 | |||||
| Operating lease right-of-use asset | 1,454,886 | 1,572,173 | |||||
| Deferred franchise and regional development costs, net of current portion | 3,259,579 | 3,827,129 | |||||
| Deposits and other assets | 286,847 | 319,460 | |||||
| Total assets | $ | 51,627,349 | $ | 60,966,527 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,097,862 | $ | 1,588,665 | |||
| Accrued expenses | 1,855,708 | 1,501,838 | |||||
| Co-op funds liability | 846,359 | 700,058 | |||||
| Payroll liabilities | 2,139,102 | 4,055,752 | |||||
| Operating lease liability, current portion | 340,885 | 194,179 | |||||
| Deferred franchise fee revenue, current portion | 2,698,531 | 2,519,018 | |||||
| Upfront regional developer fees, current portion | 178,540 | 277,394 | |||||
| Other current liabilities | 641,515 | 611,231 | |||||
| Discontinued operations current liabilities ( | 14,180,239 | 21,368,446 | |||||
| Total current liabilities | 23,978,741 | 32,816,581 | |||||
| Operating lease liability, net of current portion | 1,696,293 | 1,815,527 | |||||
| Deferred franchise fee revenue, net of current portion | 9,861,323 | 10,899,271 | |||||
| Upfront regional developer fees, net of current portion | 215,683 | 355,556 | |||||
| Total liabilities | 35,752,040 | 45,886,935 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity: | |||||||
| Series A preferred stock, | — | — | |||||
| Common stock, | 15,755 | 15,471 | |||||
| Additional paid-in capital | 52,766,531 | 52,026,407 | |||||
| Treasury stock 1,556,373 shares and 1,329,089 shares, at cost, respectively | (14,088,928 | ) | (12,192,081 | ) | |||
| Accumulated deficit | (22,843,049 | ) | (24,795,205 | ) | |||
| Total The Joint Corp. stockholders' equity | 15,850,309 | 15,054,592 | |||||
| Non-controlling Interest | 25,000 | 25,000 | |||||
| Total equity | 15,875,309 | 15,079,592 | |||||
| Total liabilities and stockholders' equity | $ | 51,627,349 | $ | 60,966,527 | |||
| THE JOINT CORP. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenues: | |||||||||||||||
| Royalty fees | $ | 8,327,549 | $ | 8,133,121 | $ | 16,359,838 | $ | 16,204,107 | |||||||
| Franchise fees | 750,587 | 768,100 | 1,895,655 | 1,596,619 | |||||||||||
| Advertising fund revenue | 3,715,837 | 2,332,695 | 7,362,920 | 4,640,197 | |||||||||||
| Software fees | 1,547,331 | 1,481,661 | 3,082,232 | 2,943,628 | |||||||||||
| Other revenues | 840,610 | 554,692 | 1,301,502 | 963,309 | |||||||||||
| Total revenues | 15,181,914 | 13,270,270 | 30,002,147 | 26,347,860 | |||||||||||
| Cost of revenues: | |||||||||||||||
| Franchise and regional development cost of revenues | 2,070,339 | 2,350,613 | 4,340,097 | 4,901,848 | |||||||||||
| IT cost of revenues | 406,911 | 421,994 | 859,808 | 842,885 | |||||||||||
| Total cost of revenues | 2,477,250 | 2,772,607 | 5,199,905 | 5,744,733 | |||||||||||
| Selling and marketing expenses | 4,886,151 | 3,483,844 | 8,603,055 | 6,988,994 | |||||||||||
| Depreciation and amortization | 422,861 | 402,295 | 819,554 | 764,225 | |||||||||||
| General and administrative expenses | 7,556,216 | 7,745,251 | 14,641,202 | 14,660,196 | |||||||||||
| Total selling, general and administrative expenses | 12,865,228 | 11,631,390 | 24,063,811 | 22,413,415 | |||||||||||
| Net loss on disposition or impairment | 208,093 | 4,440 | 233,420 | 6,413 | |||||||||||
| (Loss) income from continuing operations | (368,657 | ) | (1,138,167 | ) | 505,011 | (1,816,701 | ) | ||||||||
| Other income, net | 126,438 | 159,922 | 366,673 | 345,839 | |||||||||||
| (Loss) income before income tax expense | (242,219 | ) | (978,245 | ) | 871,684 | (1,470,862 | ) | ||||||||
| Income tax expense | 9,108 | 11,390 | 20,220 | 24,794 | |||||||||||
| Net (loss) income from continuing operations | (251,327 | ) | (989,635 | ) | 851,464 | (1,495,656 | ) | ||||||||
| Discontinued operations: | |||||||||||||||
| Income from discontinued operations before income tax expense | 901,789 | 1,183,199 | 1,280,502 | 2,760,428 | |||||||||||
| Income tax (benefit) expense from discontinued operations | (2,559 | ) | 100,201 | 179,810 | 203,613 | ||||||||||
| Net income from discontinued operations | 904,348 | 1,082,998 | 1,100,692 | 2,556,815 | |||||||||||
| Net income | $ | 653,021 | $ | 93,363 | $ | 1,952,156 | $ | 1,061,159 | |||||||
| Net (loss) income from continuing operations per common share: | |||||||||||||||
| Basic | $ | (0.01 | ) | $ | (0.06 | ) | $ | 0.06 | $ | (0.10 | ) | ||||
| Diluted | $ | (0.01 | ) | $ | (0.06 | ) | $ | 0.06 | $ | (0.10 | ) | ||||
| Net income from discontinued operations per common share: | |||||||||||||||
| Basic | $ | 0.06 | $ | 0.07 | $ | 0.08 | $ | 0.17 | |||||||
| Diluted | $ | 0.06 | $ | 0.07 | $ | 0.08 | $ | 0.17 | |||||||
| Net income per common share: | |||||||||||||||
| Basic | $ | 0.05 | $ | 0.01 | $ | 0.14 | $ | 0.07 | |||||||
| Diluted | $ | 0.05 | $ | 0.01 | $ | 0.14 | $ | 0.07 | |||||||
| Basic weighted average shares | 14,244,929 | 15,326,317 | 14,213,195 | 15,256,755 | |||||||||||
| Diluted weighted average shares | 14,246,993 | 15,400,408 | 14,216,232 | 15,328,198 | |||||||||||
| THE JOINT CORP. CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) | ||||||||
| Six Months Ended June 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities: | ||||||||
| Net income | $ | 1,952,156 | $ | 1,061,159 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 829,001 | 807,730 | ||||||
| Net loss on disposition or impairment | 1,427,651 | 2,892,265 | ||||||
| Net franchise fees recognized upon termination of franchise agreements | (395,159 | ) | (174,285 | ) | ||||
| Provision for credit losses | 122,823 | — | ||||||
| Stock-based compensation expense | 703,180 | 624,929 | ||||||
| Changes in operating assets and liabilities, net of acquisitions: | ||||||||
| Accounts receivable | 454,019 | 1,558,183 | ||||||
| Prepaid expenses and other current assets | (833,199 | ) | (1,743,981 | ) | ||||
| Deferred franchise costs | 408,499 | 183,839 | ||||||
| Deposits and other assets | 34,849 | 18,332 | ||||||
| Accounts payable | (607,825 | ) | (91,075 | ) | ||||
| Accrued expenses | 629,565 | (3,408,504 | ) | |||||
| Payroll liabilities | (2,560,203 | ) | (1,446,598 | ) | ||||
| Operating leases | (1,615,535 | ) | (2,719,624 | ) | ||||
| Deferred revenue | (625,793 | ) | (508,565 | ) | ||||
| Upfront regional developer fees | (238,727 | ) | (145,605 | ) | ||||
| Other liabilities | 1,030,748 | 259,795 | ||||||
| Net cash provided by (used in) operating activities | 716,050 | (2,832,005 | ) | |||||
| Cash flows from investing activities: | ||||||||
| Proceeds from sale of clinics | 1,160,284 | 7,778,287 | ||||||
| Purchase of property and equipment | (490,858 | ) | (836,545 | ) | ||||
| Net cash provided by investing activities | 669,426 | 6,941,742 | ||||||
| Cash flows from financing activities: | ||||||||
| Payments of finance lease obligation | — | (4,354 | ) | |||||
| Purchases of treasury stock under employee stock plans | (74,983 | ) | (8,440 | ) | ||||
| Purchases of common stock under share repurchase programs | (1,821,864 | ) | — | |||||
| Proceeds from exercise of stock options | 37,228 | 905,976 | ||||||
| Net cash (used in) provided by financing activities | (1,859,619 | ) | 893,182 | |||||
| (Decrease) increase in cash, cash equivalents and restricted cash | (474,143 | ) | 5,002,919 | |||||
| Cash, cash equivalents and restricted cash, beginning of period | 24,301,868 | 25,996,436 | ||||||
| Cash, cash equivalents and restricted cash, end of period | $ | 23,827,725 | $ | 30,999,355 | ||||
| Reconciliation of cash, cash equivalents and restricted cash: | June 30, 2026 | June 30, 2025 | ||||||
| Cash and cash equivalents | $ | 22,157,203 | $ | 29,811,667 | ||||
| Restricted cash | 1,670,522 | 1,187,688 | ||||||
| Cash, cash equivalents and restricted cash, end of period | $ | 23,827,725 | $ | 30,999,355 | ||||
| THE JOINT CORP. CONSOLIDATED RECONCILIATION FROM GAAP TO NON-GAAP (unaudited) | ||||||||||||||||||||||
| Three Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | |||||||||||||||||||||
| From Continuing Operations | From Discontinued Operations | Net Operations | From Continuing Operations | From Discontinued Operations | Net Operations | |||||||||||||||||
| Non-GAAP Financial Data: | ||||||||||||||||||||||
| Net (loss) income | $ | (251,327 | ) | $ | 904,348 | $ | 653,021 | $ | (989,635 | ) | $ | 1,082,998 | $ | 93,363 | ||||||||
| Net interest income | (126,439 | ) | — | (126,439 | ) | (159,922 | ) | — | (159,922 | ) | ||||||||||||
| Depreciation and amortization expense | 422,861 | 1,690 | 424,551 | 402,295 | 17,120 | 419,415 | ||||||||||||||||
| Income tax expense (benefit) | 9,108 | (2,559 | ) | 6,549 | 11,390 | 100,201 | 111,591 | |||||||||||||||
| EBITDA | 54,203 | 903,479 | 957,682 | (735,872 | ) | 1,200,319 | 464,447 | |||||||||||||||
| Stock-based compensation expense | 423,180 | — | 423,180 | 330,988 | — | 330,988 | ||||||||||||||||
| Acquisition-related expenses | 332,005 | — | 332,005 | — | — | — | ||||||||||||||||
| Net loss on disposition or impairment | 208,093 | 816,466 | 1,024,559 | 4,440 | 1,752,494 | 1,756,934 | ||||||||||||||||
| Restructuring costs | 113,451 | (24,422 | ) | 89,029 | 488,493 | 198,331 | 686,824 | |||||||||||||||
| Litigation expenses | 321,693 | 12,005 | 333,698 | — | — | — | ||||||||||||||||
| Adjusted EBITDA | $ | 1,452,625 | $ | 1,707,528 | $ | 3,160,153 | $ | 88,049 | $ | 3,151,144 | $ | 3,239,193 | ||||||||||
| Six Months Ended June 30, | |||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||
| From Continuing Operations | From Discontinued Operations | Net Operations | From Continuing Operations | From Discontinued Operations | Net Operations | ||||||||||||||||
| Non-GAAP Financial Data: | |||||||||||||||||||||
| Net income (loss) | $ | 851,464 | $ | 1,100,692 | $ | 1,952,156 | $ | (1,495,656 | ) | $ | 2,556,815 | $ | 1,061,159 | ||||||||
| Net interest (income) expense | (368,188 | ) | — | (368,188 | ) | (345,839 | ) | 238 | (345,601 | ) | |||||||||||
| Depreciation and amortization expense | 819,554 | 9,447 | 829,001 | 764,225 | 43,505 | 807,730 | |||||||||||||||
| Income tax expense | 20,220 | 179,810 | 200,030 | 24,794 | 203,613 | 228,407 | |||||||||||||||
| EBITDA | 1,323,050 | 1,289,949 | 2,612,999 | (1,052,476 | ) | 2,804,171 | 1,751,695 | ||||||||||||||
| Stock-based compensation expense | 703,180 | — | 703,180 | 624,929 | — | 624,929 | |||||||||||||||
| Acquisition-related expenses | 332,005 | — | 332,005 | — | — | — | |||||||||||||||
| Net loss on disposition or impairment | 233,420 | 1,194,230 | 1,427,650 | 6,413 | 2,885,852 | 2,892,265 | |||||||||||||||
| Restructuring costs | 740,338 | 56,784 | 797,122 | 555,577 | 269,715 | 825,292 | |||||||||||||||
| Litigation expenses | 346,694 | 421,775 | 768,469 | — | — | — | |||||||||||||||
| Adjusted EBITDA | $ | 3,678,687 | $ | 2,962,738 | $ | 6,641,425 | $ | 134,443 | $ | 5,959,738 | $ | 6,094,181 | |||||||||
THE JOINT CORP. RECONCILIATION OF OPERATING ACTIVITIES CASH FLOWS TO FREE CASH FLOW(1) (unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Cash flows provided by (used in) operating activities | $ | 2,192,220 | $ | 868,649 | $ | 716,050 | $ | (2,832,005 | ) | |||||||
| Purchase of property and equipment | (256,258 | ) | (505,040 | ) | (490,858 | ) | (836,545 | ) | ||||||||
| Free cash flow | $ | 1,935,962 | $ | 363,609 | $ | 225,192 | $ | (3,668,550 | ) | |||||||
| (1) Free cash flow represents cash flows provided by (used in) operating activities less capital expenditures. | ||||||||||||||||
1 System-wide sales include revenues at all clinics, whether operated or managed by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company’s financial performance, because these revenues are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base.
2 Comp sales include the revenues from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.
